Recognition and control of hypertension, diabetes, and dyslipidemia in patients with systemic lupus erythematosus
- PMID: 29948349
- DOI: 10.1007/s10067-018-4169-0
Recognition and control of hypertension, diabetes, and dyslipidemia in patients with systemic lupus erythematosus
Abstract
Systemic lupus erythematosus (SLE) patients have a high risk for cardiovascular events, but few studies have evaluated the recognition and none have evaluated the control of cardiovascular risk factors (RF) in SLE patients. The study aims to describe the recognition and control frequencies of systemic arterial hypertension (SAH), dyslipidemia, and diabetes mellitus (DM) in SLE patients. Of the female patients with SLE, 137 answered a questionnaire focused on general knowledge of the RF for coronary artery disease (CAD) and on recognition of the risk factors that they possess. The patient's information collected on a structured medical record was reviewed to evaluate the RF control. The mean age was 29.1 (9.6) years. Seventy patients had SAH; 85.7% recognized their condition and 71.4% had desirable blood pressure (BP) control (< 140 × 90 mmHg). From a group of 63 patients with dyslipidemia, 68.3% recognized that they had dyslipidemia and 69.8% had desirable LDL-cholesterol (< 130 mg/dL). Sixteen patients had DM; 87.5% admitted being diabetic and 50.0% had desirable glycemic control (HbA1C < 7%). Most patients were aware of presenting SAH, DM, or dyslipidemia, and the recognition frequency was higher in comparison to general population. The SAH and dyslipidemia control frequencies were higher than that described for the general population.
Keywords: Diabetes; Dyslipidemia; Hypertension; Risk factors for coronary artery disease; Systemic lupus erythematosus.
Similar articles
-
Recognition and control of hypertension, diabetes, and dyslipidemia in patients with rheumatoid arthritis.Rheumatol Int. 2018 Aug;38(8):1437-1442. doi: 10.1007/s00296-018-4084-3. Epub 2018 Jun 15. Rheumatol Int. 2018. PMID: 29907885
-
[Analysis of traditional cardiovascular risk factors in patients with systemic lupus erythematosus].Zhonghua Xin Xue Guan Bing Za Zhi. 2014 Sep;42(9):753-8. Zhonghua Xin Xue Guan Bing Za Zhi. 2014. PMID: 25511096 Chinese.
-
Evaluating the prevalence, awareness, and control of hypertension, diabetes, and dyslipidemia in Korea using the NHIS-NSC database: A cross-sectional analysis.Medicine (Baltimore). 2018 Dec;97(51):e13713. doi: 10.1097/MD.0000000000013713. Medicine (Baltimore). 2018. PMID: 30572503 Free PMC article.
-
Management of dyslipidemia in children and adolescents with systemic lupus erythematosus.Lupus. 2007;16(8):618-26. doi: 10.1177/0961203307079566. Lupus. 2007. PMID: 17711898 Review.
-
Dyslipidemia in systemic lupus erythematosus.Immunol Res. 2017 Apr;65(2):543-550. doi: 10.1007/s12026-016-8892-9. Immunol Res. 2017. PMID: 28168401 Review.
Cited by
-
Glucocorticoid treatment in SLE is associated with infections, comorbidities and mortality-a national cohort study.Rheumatology (Oxford). 2024 Apr 2;63(4):1104-1112. doi: 10.1093/rheumatology/kead348. Rheumatology (Oxford). 2024. PMID: 37439705 Free PMC article.
-
Live fast, die young: neutrophils streamline their metabolism to maximize inflammation.Infect Immun. 2025 Aug 12;93(8):e0049824. doi: 10.1128/iai.00498-24. Epub 2025 Jun 30. Infect Immun. 2025. PMID: 40586776 Free PMC article. Review.
-
Diabetes mellitus in rheumatic diseases: clinical characteristics and treatment considerations.Rheumatol Int. 2023 Dec;43(12):2167-2174. doi: 10.1007/s00296-023-05453-9. Epub 2023 Sep 17. Rheumatol Int. 2023. PMID: 37718369 Review.
-
Mortality in Antinuclear Antibody-Positive Patients with and Without Rheumatologic Immune-Related Disorders: A Large-Scale Population-Based Study.Medicina (Kaunas). 2025 Jan 2;61(1):60. doi: 10.3390/medicina61010060. Medicina (Kaunas). 2025. PMID: 39859043 Free PMC article.
-
Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus.Front Immunol. 2022 Mar 18;13:860586. doi: 10.3389/fimmu.2022.860586. eCollection 2022. Front Immunol. 2022. PMID: 35371016 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous